Volume : 12, Issue : 11, November – 2025
Title:
HERBAL INTERVENTION OF NEURODEGENERATIVE DISEASES
Authors :
Ms. E. Naga Deepthi, Yerra Shaik Jubina
Abstract :
Neurodegenerative disorders (NDs) are anticipated to become a major concern for both medicine and public health due to ongoing global demographic shifts. These disorders are characterized mainly by the degeneration or loss of neurons, which plays a critical role in severe mental illnesses. This neuronal damage results in numerous neuropsychiatric complications and permanent disabilities for affected individuals. Administering therapeutic agents to the brain in conditions like Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, and multiple system atrophy remains a significant challenge. Several plant species have shown neuroprotective effects, particularly by reducing protein misfolding, improving protein quality control mechanisms, and regulating oxidative stress. For instance, Bacopa monnieri, Curcuma longa (turmeric), Camellia sinensis (green tea), Moringa oleifera, and Withania somnifera (ashwagandha) have all exhibited effectiveness against protein aggregation and neurotoxicity observed in experimental models of Alzheimer’s, Parkinson’s, Huntington’s, and prion diseases.
Key words: Neurodegeneration, loss of neurons, Alzheimer’s disease, Huntington’s disease, phytochemicals, herbs.
.
Cite This Article:
Please cite this article in press E. Naga Deepthi et al., Herbal Intervention Of Neurodegenerative Diseases, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
1. Gadhave DG, Sugandhi VV, Kokare CR. Potential biomaterials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder multiple sclerosis. 2024.
2. Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. 2022.
3. Choonara YE, Pillay V, Du Toit LC, Modi G, Naidoo D, Ndesendo VMK, Sibambo SR. Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders. 2009.
4. Hui BSM, Zhi LR, Retinasamy T, Arulsamy A, Law CSW, Shaikh MF, Yeong KY. The role of interferon-α in neurodegenerative diseases: a systematic review. 2023.
5. Pant S, Kapri A, Nain S. Pyrimidine analogues for the management of neurodegenerative diseases. 2022.
6. Tanaka M, Toldi J, Vécsei L. Exploring the etiological links behind neurodegenerative diseases: inflammatory cytokines and bioactive kynurenines. 2020.
7. Gadhave DG, Sugandhi VV, Kokare CR. Potential biomaterials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder: Multiple sclerosis. 2024.
8. Huang P, Zhang M. Magnetic resonance imaging studies of neurodegenerative disease: from methods to translational research Neurosci. 2023.
9. Jiménez-Balado T, Eich GS. GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer’s disease Semin. 2021.
10. Shankar GM, Walsh DM. Alzheimer’s disease: synaptic dysfunction and Aβ. 2009.
11. Andreasen N, et al. Diagnostic and Statistical Manual of Mental Disorders. DSM-IV. 1994.
12. End-stage Alzheimer’s disease. Glasgow Coma Scale and the neurologic examination. Arch Neurol. 1993.
13. Becker JT, et al. The natural history of Alzheimer’s disease: description of study cohort and accuracy of diagnosis. Arch Neurol. 1994.
14. Montine TJ, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012.
15. Hyman BT, Trojanowski JQ. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012.
16. Frontiers in Pharmacology. Extract standardization and therapeutic use. 2022.
17. Boateng ID. A critical review of ginkgolic acids in Ginkgo biloba leaf extract (EGb): toxicity and technologies to remove ginkgolic acids and their promising bioactivities.
18. Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018.
19. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992.
20. Yang Y, Shi Y, Schweighauser M, Zhang X, Goedert M. Cryo-EM structures of α-synuclein filaments from Parkinson’s disease and dementia with Lewy bodies.
21. Kirmizibekmez H, Alper M, et al. Investigations on the in vivo wound healing potential of Hypericum perforatum L. J Ethnopharmacol. 2010.
22. American Herbal Pharmacopeia. St. John’s wort. Hypericum perforatum. Quality control, analytical and therapeutic monograph. American Botanical Council; 1997.
23. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992.
24. Yang Y, Shi Y, Schweighauser M, Zhang X, Goedert M. Cryo-EM structures of α-synuclein filaments from Parkinson’s disease and dementia with Lewy bodies.
25. Kirmizibekmez H, Alper M, et al. Investigations on the in vivo wound healing potential of Hypericum perforatum L. J Ethnopharmacol. 2010.
26. American Herbal Pharmacopeia. St. John’s wort. Hypericum perforatum. Quality control, analytical and therapeutic monograph. American Botanical Council; 1997.
27. Jeste DV, Barban L, Parisi J. Reduced Purkinje cell density in Huntington’s disease.
28. Kremer HP. The hypothalamic lateral tuberal nucleus: normal anatomy and changes in neurological diseases.
29. Heinsen H, Rub U, Bauer M, et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington’s disease. Acta Neuropathol (Berl). 1999.
30. Macdonald V. Significant cant loss of pyramidal neurons in the angular gyrus of patients with Huntington’s disease. Neuropathol Appl Neurobiol. 1997.
31. Gutekunst CA, Norflus F, Hersch S. The neuropathology of Huntington’s disease. In: Bates G, Harper P, Jones L, editors. Huntington’s disease. New York: Oxford University Press; 2002.
32. Mayo Clinic. Symptoms & causes of ALS (muscle weakness, twitching, speech/swallowing difficulties, progressive worsening).
33. Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1998. Dai YL, et al. Chamomile: a review of its traditional uses, chemical constituents, and pharmacological activities. PMC; 2022.
34. Gilman S, Low P. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology.
35. Gilman S, Wenning GK, Low PA. Second consensus statement on the diagnosis of multiple system atrophy. TS Vo et al. Review on Turmeric Chemical Components. 2021.
36. Bhandari J, et al. Spinocerebellar ataxia: late-stage complications. StatPearls; 2023.
37. Cui ZT, et al. Spinocerebellar ataxias: from pathogenesis to recent advances. 2024.
38. Zhao DD, Wang J, Liu S, et al. Chemical components and pharmacological activities of the genus Paeonia.
39. McGarry ME, et al. Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington’s disease. 2020.
17. Nannar A. Review on pharmaceutical gelling agents. Phys Sci Biophys J. 2024;8(1):1–11.